肿瘤

晚期ALK阳性非小细胞肺癌接受培美曲塞为基础化疗的效果

作者:A. T. Shaw等 来源:Ann Oncol 日期:2012-08-15
导读

         晚期ALK阳性非小细胞肺癌接受培美曲塞为基础化疗的效果

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

晚期ALK阳性非小细胞肺癌接受培美曲塞为基础化疗的效果

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
Abstract
Background Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib. To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patients who had been treated with pemetrexed-based chemotherapy for advanced NSCLC.
Patients and methods We identified 121 patients with advanced, ALK-positive NSCLC in the USA, Australia, and Italy. For comparison, we evaluated 266 patients with advanced, ALK-negative, epidermal growth factor receptor (EGFR)-wild-type NSCLC, including 79 with KRAS mutations and 187 with wild-type KRAS (WT/WT/WT). We determined PFS on different pemetrexed regimens.
Results Among 70 ALK-positive patients treated with a platinum/pemetrexed regimen, the median PFS (mPFS) was 7.3 months (95% confidence interval (CI) 5.5–9.5). The mPFS of 51 ALK-positive patients treated with single-agent pemetrexed or nonplatinum/pemetrexed combinations was 5.5 months (2.8–9.0). For ALK-negative patients, PFS on all pemetrexed-based regimens was similar to that of ALK-positive patients, except in the specific setting of first-line platinum/pemetrexed where the mPFS was only 4.2 and 5.4 months in KRAS and WT/WT/WT patients, respectively. However, among patients with a never/light-smoking history (0–10 pack-year smoking history) treated with first-line platinum/pemetrexed, there was no difference in PFS between ALK-positive and ALK-negative patients.
Conclusions PFS on pemetrexed or nonplatinum/pemetrexed combinations was similar in ALK-positive and ALK-negative patients. PFS on first-line platinum/pemetrexed may be prolonged in never/light-smoking patients regardless of ALK status.
原文链接:http://annonc.oxfordjournals.org/content/early/2012/08/09/annonc.mds242.abstract

分享:

评论

我要跟帖
发表
回复 小鸭梨
发表

copyright©医学论坛网 版权所有,未经许可不得复制、转载或镜像

京ICP证120392号  京公网安备110105007198  京ICP备10215607号-1  互联网药品信息服务资格证书:(京)-非经营性-2017-0056
//站内统计 //百度统计 //谷歌统计 //站长统计
*我要反馈: 姓    名: 邮    箱: